https://www.selleckchem.com/products/Zileuton.html
Two independent reviewers determined the eligibility of the studies and will independently extract the data. Risk of bias will be assessed using the COSMIN risk-of-bias checklist, and the quality of the results will be assessed using specific COSMIN quality criteria. It is not necessary to obtain ethical approval for this systematic review protocol. The results will be published in a peer-reviewed journal and presented at a relevant conference. CRD42020149120. CRD42020149120. Prophylactic drugs currently used for migraine treatment are
Like
Comment
Share
